The Department of Health and Social Care (DHSC) has announced that that the following product will have a redetermination due to late notification of a price increase, this will apply from December 2022 to February 2023:

Mebeverine 50mg/5ml oral suspension sugar free (300ml) – £205.70 (instead of £187.00)

Pharmacy contractors should note that this is not reflected in December 2022, January 2023 or February 2023 Drug Tariffs. Any necessary price adjustments will be included in February 2023 Prescriptions Schedule of Payment. The payments will appear as ‘Adjustment drugs‘ and ‘Adjustment fees‘ (if applicable).

PSNC has raised concerns with DHSC about the accuracy of certain product and pricing information held on dm+d. PSNC is in discussion with DHSC regarding improvements to the data gathering and checking processes for dm+d database, managed by NHS Business Services Authority (NHSBSA).

The post Redetermination for Mebeverine 50mg/5ml oral suspension sugar free appeared first on PSNC Website.